Biogen price target lowered to $305 from $310 at Canaccord

Canaccord analyst Sumant Kulkarni lowered the firm’s price target on Biogen to $305 from $310 and keeps a Buy rating on the shares. The firm believes Leqembi remains a solid long-term driver especially if maintenance dosing and the subcutaneous formulation are approvedand as a result the firm continues to believe the stock could work well for patient investors.